Co-administration of dapagliflozin and linagliptin in type 2 diabetes
Co-administration of dapagliflozin (in Xigduo) with linagliptin (Trajenta) is clinically used for type 2 diabetes management. (pubmed.ncbi.nlm.nih.gov) In randomized clinical trials, add-on dapagliflozin to metformin plus linagliptin (and/or fixed-dose dapagliflozin/linagliptin) produced additional glucose-lowering versus linagliptin alone with no symptomatic hypoglycemia reported. (pubmed.ncbi.nlm.nih.gov)
Medication selection algorithm
Dapagliflozin and linagliptin should be selected as complementary glucose-lowering agents with different mechanisms of action. (medils.com) When intensification beyond metformin is needed, combination therapy with agents from distinct medication classes is recommended in adults with type 2 diabetes. (medils.com)
Key evidence supporting this recommendation
In a phase III randomized trial of inadequate control on metformin plus linagliptin, a fixed-dose combination of dapagliflozin/linagliptin (10/5 mg) reduced HbA1c from baseline to week 24 with a least squares mean difference of −0.88% versus linagliptin plus placebo. (pubmed.ncbi.nlm.nih.gov) In the same trial, the proportion achieving HbA1c <7.0% at week 24 was higher with dapagliflozin/linagliptin than with linagliptin plus placebo (44.8% vs 18.6%). (pubmed.ncbi.nlm.nih.gov) The phase III trial reported similar overall adverse-event profiles between groups and reported no cases of symptomatic hypoglycemia. (pubmed.ncbi.nlm.nih.gov) In an additional randomized phase III trial comparing dapagliflozin/linagliptin versus dapagliflozin/vildagliptin as add-on to metformin, dapagliflozin/linagliptin produced a greater HbA1c reduction from baseline to week 16 (mean reduction −1.59% vs −1.25%). (pubmed.ncbi.nlm.nih.gov)
Monotherapy versus combination therapy
Combination therapy with dapagliflozin plus linagliptin is used when monotherapy is insufficient for achieving individualized glycemic targets. (medils.com) Add-on dapagliflozin to linagliptin-based therapy has demonstrated additional glycemic efficacy relative to linagliptin alone in randomized trials. (pubmed.ncbi.nlm.nih.gov)
Important clarifications and nuances
Xigduo provides dapagliflozin plus metformin. (pubmed.ncbi.nlm.nih.gov) Trajenta provides linagliptin. (pubmed.ncbi.nlm.nih.gov) A direct clinical-trial basis exists for the specific combination of dapagliflozin with linagliptin, including as fixed-dose dapagliflozin/linagliptin studied in patients already receiving metformin and linagliptin. (pubmed.ncbi.nlm.nih.gov)
Treatment initiation thresholds and practical criteria
Dapagliflozin/linagliptin can be used as an intensification strategy when individualized glycemic goals are not met on existing therapy. (medils.com) Renal function should be assessed before initiating or continuing dapagliflozin-containing therapy. (medils.com)
Common pitfalls to avoid
Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be avoided in insulin-deficient states where risk of diabetic ketoacidosis is increased. (medils.com) Hypoglycemia risk is generally low with dapagliflozin and linagliptin combinations in trials when used without insulin or sulfonylureas. (pubmed.ncbi.nlm.nih.gov)
Target blood pressure and glycemic goals
Glycemic targets should be individualized in adults with type 2 diabetes. (medils.com) HbA1c targets and treatment adjustments should be guided by attainment and durability of individualized goals. (medils.com)